Search

Your search keyword '"Hundemer, M"' showing total 158 results

Search Constraints

Start Over You searched for: Author "Hundemer, M" Remove constraint Author: "Hundemer, M"
158 results on '"Hundemer, M"'

Search Results

2. Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)

3. P429: CLONALLY RESOLVED SINGLE-CELL MULTI-OMICS IDENTIFIES LEUKEMIA SURFACE ANTIGENS

4. P447: BCL2-INHIBITION TARGETS LEUKEMIC STEM CELLS IN ACUTE MYELOID LEUKEMIA INDEPENDENT OF MONOCYTIC BLAST POPULATIONS

23. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

25. TRANSCRIPTIONAL AND GENOMIC INTRA-TUMOR HETEROGENEITY DRIVES SUBCLONE SPECIFIC DRUG RESPONSES IN DIFFUSE LARGE B CELL LYMPHOMA

28. B034 A Gene Expression—Based Proliferation Index as Independent Prognostic Factor in Multiple Myeloma

29. A167 BMP6: A Novel Antiangiogenic, Antiproliferative, and Prognostic Factor Expressed by Myeloma Cells

30. B050 Angiogenesis in Multiple Myeloma: Induction by Normal Plasma Cell — and Aberrantly Expressed Genes

31. B033 Aurora-Kinase Inhibition for Tailored Risk-Adapted Treatment of Multiple Myeloma

34. CD200 is a new prognostic factor in multiple myeloma

36. Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)

37. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

40. The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities.

41. CD8 + CD28 - regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study.

43. The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature.

44. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.

45. Idecabtagene Vicleucel Is Well Tolerated and Effective in Relapsed/Refractory Myeloma Patients with Prior Allogeneic Stem Cell Transplantation.

46. Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD.

47. Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax.

48. Clonally resolved single-cell multi-omics identifies routes of cellular differentiation in acute myeloid leukemia.

49. Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma.

Catalog

Books, media, physical & digital resources